References
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86
- NCI dictionary of Cancer Terms. National Cancer Institute; National Institute of Health. Bethesda, Maryland. 2017. https://www.cancer.org/publications/dictionaries/cancer-terms. Accessed April 5, 2017
- Esserman LJ, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013;310:797-8
- Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013;63:597-603
- Yabroff KR, Lund J, Kepka D, et al. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 2011;20:2006-14
- Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106-31
- Dahabreh IJ, Chung M, Balk EM, et al. Active surveillance in men with localized prostate cancer: a systematic review. Ann Intern Med 2012;156:582-90
- Eldefrawy A, Katkoori D, Abramowitz M, et al. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. Urol Oncol 2013;31:576-80
- Dall’Era MA, Evans CP. The economics of active surveillance for prostate cancer. In: Klotz L, editor. Active surveillance for localized prostate cancer: a new paradigm for localized prostate cancer. 1st ed. New York, NY: Humana Press; 2012. p 179-85
- Laviana AA, Ilg AM, Veruttipong D, et al. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. Cancer 2016;122:447-55
- Molinier L, Castelli C, Bauvin E, et al. Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data. Eur J Health Econ 2011;12:363-71
- D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74
- Aizer AA, Gu X, Chen MH, et al. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw 2015;13:61-8
- Crawford ED, Black L, Eaddy M, et al. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis 2010;13:162-7
- Corcoran AT, Peele PB, Benoit RM. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Urology 2010;76:703-7
- Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 2007;109:518-27